# Sanofi Options First Immunology Candidate from Recursion AI Collaboration

- URL: https://stocks.freetheai.org/news/sanofi-options-first-immunology-candidate-from-recursion-ai-collaboration-211af4
- Published: 2026-10-15T12:45:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:RXRX](https://stocks.freetheai.org/symbols/NASDAQ-RXRX), [EURONEXT:SAN](https://stocks.freetheai.org/symbols/EURONEXT-SAN)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) disclosed that Sanofi SA (EURONEXT:SAN) has exercised its option on an initial drug candidate generated through their ongoing research partnership. The asset is a potential first-in-class oral small molecule intended to treat inflammatory diseases by targeting two biological markers at once. Sanofi's selection triggers a $10 million milestone payment to Recursion, bringing its total revenue collected from the deal to $144 million.

The candidate represents an operational success for Recursion's AI-assisted discovery platform, which worked to resolve intricate design constraints. Recursion will record the $10 million in revenue during the third quarter of 2026. Because Recursion has fulfilled its technical responsibilities for this specific compound, any subsequent milestone payments—which could exceed $300 million—plus double-digit royalties on future sales will directly contribute to profit.

Sanofi assumes full responsibility for all upcoming development, clinical trials, and potential marketing efforts. A Phase 1 clinical trial is slated to start in 2027. Over the next 12 months, investors can watch for potential development progress across other joint programs in the partnership.

## Key points

- Sanofi optioned an oral small molecule candidate targeting inflammatory diseases developed using Recursion's AI platform.
- Recursion receives a $10 million milestone payment, bringing total cash received from the collaboration to $144 million.
- Sanofi will fully fund and run future development, with Phase 1 clinical trials targeted for 2027.
- Recursion remains eligible for more than $300 million in potential future milestones plus double-digit sales royalties.

## Questions and answers

### What did Sanofi announce regarding Recursion Pharmaceuticals?

Sanofi optioned its first drug candidate from its collaboration with Recursion Pharmaceuticals. The candidate is a potential first-in-class oral small molecule for inflammatory diseases.

### How much money does Recursion receive from Sanofi's option exercise?

Recursion will receive a $10 million milestone payment, recognized in the third quarter of 2026. This brings total payments under the collaboration to $144 million, with up to $300 million in potential future milestones.

### When will clinical trials begin for the new drug candidate?

Sanofi plans to begin Phase 1 clinical trials for the newly optioned immunology drug candidate in 2027.